Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
The expansion of the indication was supported by positive data from the KarMMa-3 study.
Advertisement
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
The 11-member panel of independent experts voted eight in favor and three against.
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
S. Vincent Rajkumar, MD, a myeloma clinician and researcher, currently serves as a Professor of Medicine at the Mayo Clinic.
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
A phase I clinical trial on IDP-023 is currently enrolling patients.
The target action date for the FDA’s decision is August 22, 2024.
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
The study used public data from various online sources related to approved CAR-T therapies for MM.
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.